Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
Powell stresses the central bank's independence in a speech that comes amid continuous pressure from the White House to cut interest rates.The Fedread more
The Senate is expected to pass its own version of the border aid legislation, while the Trump administration has threatened to veto both bills.Politicsread more
Markets in Asia fell on Wednesday morning after U.S. Federal Reserve Chairman Jerome Powell tempered expectations for a potential interest rate cut.Asia Marketsread more
In a text message, Grisham confirmed to CNBC that she will still be working for the first lady even as she takes on her new roles.Politicsread more
Acting Customs and Border Protection Commissioner John Sanders is resigning amid the furor over the Trump administration's treatment of migrant children.Politicsread more
NBC is taking the office back from Netflix as it seeks to bolster its own streaming service launching in 2020.Technologyread more
Wayfair employees plan to walk out tomorrow, after no action was taken in response to their opposition to the company supplying border detention camps with beds for children.Retailread more
Medical device maker Medtronic posted a better-than-expected quarterly profit on Tuesday, helped by strong performance across all segments.
The company's top-selling cardiac and vascular unit that makes defibrillators, pace-makers, heart valves and stents raked in revenue of $2.86 billion, beating analysts' estimate of $2.84 billion, according to IBES data from Refinitiv.
Medtronic's minimally invasive therapies business, which makes surgical instruments and endoscopy products, brought in a revenue of $2.05 billion, ahead of analysts' estimate of $2.01 billion.
The company also raised its full-year organic revenue forecast to a range of 5.0 percent to 5.5 percent from 4.5 percent to 5.0 percent.
Net income attributable to the company fell to $1.12 billion, or 82 cents per share, in the second quarter ended Oct. 26, from $2.02 billion, or $1.48 per share, a year earlier.
The company had a $235 million income tax provision in the reported quarter, compared with a $285 million tax benefit in the year-ago quarter.
Excluding items, Medtronic earned $1.22 per share, beating analysts' expectations of $1.15 per share.
Net sales rose 6 percent to $7.48 billion, above estimates of $7.35 billion.